Table 3.
Distribution of number of patients for exact matching variables at cohort entry date
| Pioglitazone cohort (no (%) of patients) | Standardised difference | |||||
|---|---|---|---|---|---|---|
| Exposed to pioglitazone (n=56 337) | Not exposed to pioglitazone (nearest match cohort; n=56 337) | Not exposed to pioglitazone (multiple match cohort; n=317 109) | Nearest match cohort | Multiple match cohort | ||
| Type of treatment change at cohort entry date | ||||||
| Add-on | 36 237 (64.32) | 36 237 (64.32) | 212 245 (66.93) | 0.00 | 0.00 | |
| Switch | 20 100 (35.68) | 20 100 (35.68) | 104 864 (33.07) | 0.00 | 0.00 | |
| Use of another thiazolidinedione before cohort entry date | ||||||
| Never | 41 847 (74.28) | 41 847 (74.28) | 276 452 (87.18) | 0.00 | 0.00 | |
| Ever | 14 490 (25.72) | 14 490 (25.72) | 40 657 (12.82) | 0.00 | 0.00 | |
| Diabetes treatment taken immediately before cohort entry date* | ||||||
| Metformin only | 16 526 (29.33) | 16 526 (29.33) | 115 003 (36.27) | 0.00 | 0.00 | |
| Sulphonylureas only | 6110 (10.85) | 6110 (10.85) | 36 673 (11.56) | 0.00 | 0.00 | |
| Metformin and sulphonylureas | 14 277 (25.34) | 14 277 (25.34) | 61 494 (19.39) | 0.00 | 0.00 | |
| Insulin (only or in combination) | 2705 (4.80) | 2705 (4.80) | 16 940 (5.34) | 0.00 | 0.00 | |
| Other drugs (one drug only or combination | 10 062 (17.86) | 10 062 (17.86) | 31 743 (10.01) | 0.00 | 0.00 | |
| No treatment | 6657 (11.82) | 6657 (11.82) | 55 256 (17.42) | 0.00 | 0.00 | |
*Treatments initiated at cohort entry date not included.